Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
POPULAR rice brand Tilda and the United Nations World Food Programme (UNWFP) are taking part in an initiative to provide nutritious meals for underprivileged families.
Asian chef Cyrus Todiwala is part of the ‘Helping Mums Together’ campaign which sees specialised meals aimed at combating low birth weight in Bangladesh for the sixth year.
Each specially marked Tilda Pure Basmati Rice pack will fund an equivalent of one nutrition-boosting meal to a new or expectant mother or young child as the Asian country fights malnutrition and low birth weight.
The meals are given in the form of a super cereal for mothers and a super cereal plus for children, which are vitamin- and mineral-enriched porridge.
“It is great to see a company as influential as Tilda is working with the World Food Programme for those in need,” Todiwala said.
“Nutrition is important to children in their first 1,000 days, in ensuring proper physical and cognitive development, and the ‘Helping Mums Together’ campaign directly targets this vulnerable group of people.”
Every month, the WFP provides specialised nutrition to more than 225,000 women and children at 34 nutrition centres in refugee camps in Cox’s Bazar, Bangladesh, according to a statement.
Tilda, with more than 50 years of experience within the rice category, has donated the equivalent of almost six million nutrition-boosting meals through the programme in the past five years.
Todiwala, who runs a restaurant in London and also appears on TV cookery shows, will create and share one of his favourite recipes as part of the collaboration.
“The work that we do with both refugees and local people in and around Cox’s Bazar is a vital part of our programme,” said Jane Howard, head of communications, advocacy and marketing at the World Food Programme’s London Office.
“Nutrition and food security are at crisis levels in Cox’s Bazar with 80 per cent of new arrivals fully dependent on humanitarian assistance. Tilda’s support over the past five years has contributed to the wellbeing of those most at risk.”
“We are actively working to provide more economic opportunities, such as setting up a farmers’ market where local smallholders, including women who have received WFP training in entrepreneurship, can sell their produce to refugees.
The special packs of Tilda Pure Basmati Rice and Tilda Basmati Rice pouches are available at all major retailers.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.